- Home
- SAGE vs CSTL Comparison
SAGE vs CSTL Comparison
Compare SAGE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- CSTL
- Stock Information
- Founded
- SAGE 2010
- CSTL 2007
- Country
- SAGE United States
- CSTL United States
- Employees
- SAGE N/A
- CSTL N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- SAGE Health Care
- CSTL Health Care
- Exchange
- SAGE Nasdaq
- CSTL Nasdaq
- Market Cap
- SAGE 571.1M
- CSTL 561.9M
- IPO Year
- SAGE 2014
- CSTL 2019
- Fundamental
- Price
- SAGE $9.12
- CSTL $16.53
- Analyst Decision
- SAGE Hold
- CSTL Strong Buy
- Analyst Count
- SAGE 18
- CSTL 6
- Target Price
- SAGE $9.89
- CSTL $37.67
- AVG Volume (30 Days)
- SAGE 1.8M
- CSTL 396.8K
- Earning Date
- SAGE 07-30-2025
- CSTL 08-04-2025
- Dividend Yield
- SAGE N/A
- CSTL N/A
- EPS Growth
- SAGE N/A
- CSTL N/A
- EPS
- SAGE N/A
- CSTL N/A
- Revenue
- SAGE $47,404,000.00
- CSTL $347,083,000.00
- Revenue This Year
- SAGE $101.71
- CSTL N/A
- Revenue Next Year
- SAGE $42.30
- CSTL $1.36
- P/E Ratio
- SAGE N/A
- CSTL N/A
- Revenue Growth
- SAGE N/A
- CSTL 38.43
- 52 Week Low
- SAGE $4.62
- CSTL $15.45
- 52 Week High
- SAGE $13.47
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SAGE 66.62
- CSTL 34.83
- Support Level
- SAGE $9.10
- CSTL $19.29
- Resistance Level
- SAGE $9.36
- CSTL $20.26
- Average True Range (ATR)
- SAGE 0.10
- CSTL 0.70
- MACD
- SAGE -0.09
- CSTL -0.35
- Stochastic Oscillator
- SAGE 29.69
- CSTL 4.44
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.